An Update of Pharmacological & Non-Pharmacological Therapies for COVID-19 Pandemic Trivia

Authors

Abstract:

The whole planet is facing one of the scariest pandemic situations in this era. On 11th February, 2020 the World Health Organization announced the name of an unknown disease as COVID-19, which is caused by the ssRNA virus SARS-CoV-2 (formally recognized as a sister of SARS-CoV and MERS-CoV). The epicenter of this disease is Wuhan, Hubei Province, China. COVID-19 can affect all age groups but particularly affects immune compromised persons and those more than 60 years of age with co-morbid conditions like heart disease, diabetes, cancer, or HIV/AIDS. It is highly contagious disease that involves mild to severe respiratory symptoms and breathing problems. The transmission occurs through respiratory droplets and person-to-person contact. As SARS-CoV-2 is a new strain of β-coronavirus that spreads from animals to humans via an unknown intermediate host, no vaccines have been developed yet and only supportive treatment is given to the infected patients. Some antiviral drugs are approved and prescribed to the patients and some others are still under investigation. Therefore, social distancing, home quarantine, and proper healthy lifestyle are the best current options to avoid further spread of this pervasive virus.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Proposed pharmacological treatments for COVID-19: previously confirmed drugs

Background:     The outbreak of severe acute respiratory syndrome coronavirus-2, also called COVID-19, first appeared in December 2019 in Wuhan, China. COVID-19 is an enveloped single-stranded RNA virus, which has affected more than 14 million people around the world and caused a high rate of mortality. It is notable that discovering new drugs and vaccines against SARS-CoV2 is time consuming. ...

full text

9 Non - pharmacological therapies in osteoarthritis

Non-pharmacological therapies are very important in osteoarthritis. Each form of this treatment should be individually devised, taking into account the anatomical distribution, the phase and the progression rate of the disease. Indications, contraindications, dosage and precautions are as important in non-pharmacological therapy as they are in drug treatment. Therapeutic exercises decrease pain...

full text

23 Non - Pharmacological Therapies in Pain Management

Pain is an unpleasant feeling and emotional experience that is related to real or potential tissue damage or a damage that is defined similarly. Pain is mostly subjective (Merskey, Bogduk 1986). From many points of view, the pain is a common symptom intended for seeking aid (Dickens et al. 2002). International Association for the Study of Pain (IASP) defines the pain as “an unpleasant emotional...

full text

Pharmacological therapies for unconjugated hyperbilirubinemia.

Severe unconjugated hyperbilirubinemia, seen mainly in neonates, may cause kernicterus and death. Conventional treatment for severe unconjugated hyperbilirubinemia consists of phototherapy and exchange transfusion. Phototherapy, however, has several known disadvantages while exchange transfusion is associated with a significant morbidity, and even mortality. These harmful effects indicate the n...

full text

Pharmacological management of Cushing's syndrome: an update.

The treatment of choice for Cushing's syndrome remains surgical. The role for medical therapy is twofold. Firstly it is used to control hypercortisolaemia prior to surgery to optimize patient's preoperative state and secondly, it is used where surgery has failed and radiotherapy has not taken effect. The main drugs used inhibit steroidogenesis and include metyrapone, ketoconazole, and mitotane....

full text

Pharmacoresistant Epilepsy: A Current Update on Non-Conventional Pharmacological and Non-Pharmacological Interventions

Uncontrolled seizure or epilepsy is intricately related with an increase risk of pharmacoresistant epilepsy. The failure to achieve seizure control with the first or second drug trial of an anticonvulsant medication given at the appropriate daily dosage is termed as pharmacoresistance, despite the fact that these drugs possess different modes of action. It is one of the devastating neurological...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 6  issue Special Issue on COVID-19

pages  0- 0

publication date 2020-06

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023